Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ianalumab · VAY-736

Monoclonal antibody · Antagonist of B-cell activating factor receptor (TNFRSF13C) · developed by Novartis Pharmaceuticals

Phase 3 Most advanced trial
NVS Developer
1 Registered trials

What is Ianalumab?

Ianalumab is a fully human monoclonal antibody that binds the B-cell activating factor receptor (BAFF-R, TNFRSF13C), inhibiting BAFF binding and BAFF-R-mediated signaling that supports B-cell proliferation and survival. It is being studied in primary immune thrombocytopenia (ITP).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VAY-736
Drug type
Monoclonal antibody
Targets
B-cell activating factor receptor (TNFRSF13C)
Mechanism
Antagonist of B-cell activating factor receptor (TNFRSF13C)
Pathways
BAFF/BAFF-R signaling, B-cell proliferation and survival
Therapy area
Hematology, Immunology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
ZN2GQ3II96

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05653349 Phase 3 Primary Immune Thrombocytopenia (ITP) Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Immune Thrombocytopenia (ITP)

More from Novartis Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Ianalumab

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.